Opinion

Video

Examining Trial Data on Omaveloxolone Efficacy

A physician examines clinical trial results that impact their approach to treating patients with Friedreich ataxia.

  • In 2023, a propensity matched comparison of MOXIe extension patients to an untreated cohort found a significant slowing of disease progression per mFARS of 3.0 points compared to 6.6 points, respectively. Are these results clinically meaningful for patients and how does this relate to your everyday clinical practice?
Related Videos
Susan Perlman, MD, an expert on Friedreich's ataxia
Ana Baramidze, MD, PhD
5 KOLs are featured in this series.
5 KOLs are featured in this series.
This series features 1 KOL.
1 KOL is featured in this series.
Ticiana Leal, MD, Emory Winship Cancer Institute
Javed Butler, MD
Related Content
Physician holding a tablet with data anaytics | Image credit: tonefotografia - stock.adobe.com
September 13th 2024

Keeping Up With Evolving Data to Better Cancer Care

Laura Joszt, MA
It’s hard for practicing oncologists to stay on top of the latest clinical data, but good partnerships and clinical decision support tools can assist.
Managed Care Cast logo
July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Sparkling telomere | Image Credit: Dr_Microbe - stock.adobe.com
September 13th 2024

THIO Combo Yields Survival Benefit in Advanced NSCLC

Russ Conroy
Developers anticipate releasing full efficacy results from the phase 2 THIO-101 trial later this year.
Managed Care Cast
May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi
In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
STS word cloud | Image Credit: Colored Lights-stock.adobe.com
September 13th 2024

Elraglusib Granted FDA Orphan Drug Status in Soft Tissue Sarcoma

Jordyn Sava
The FDA granted orphan drug designation for elraglusib, a novel drug for treating advanced soft tissue sarcoma.
Doctor holding heart | Image Credit: © Pana Studio - stock.adobe.com
September 12th 2024

Acalabrutinib vs Ibrutinib: Real-World Insights Into Safety Differences for Patients With CLL

Kimberly Rath, PharmD
The latest study findings suggest that acalabrutinib may be a safer option than ibrutinib for patients with chronic lymphocytic leukemia, offering a lower risk of serious cardiovascular and infection-related adverse events.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo